JVM-3 Cells
General information
| Description | JVM-3 is a human B-cell prolymphocytic leukemia (B-PLL) cell line established from the peripheral blood of a 73-year-old Caucasian male patient. The line grows in suspension as lymphoblastoid cells either singly or in loose clumps and is a widely used model for B-PLL, a rare and aggressive mature B-cell leukemia. JVM-3 harbors TP53 mutations (p.Pro1435Leu heterozygous and p.Lys601Asn heterozygous), which inactivate the tumor suppressor function of p53 and are associated with resistance to chemotherapy in B-cell malignancies. The line is cultured in 90% RPMI 1640 + 10% heat-inactivated FBS. JVM-3 is applicable in B-PLL research, including studies of mature B-cell leukemia biology, TP53 mutation-associated drug resistance, BCR signalling pathway analysis, evaluation of targeted therapies (BTK inhibitors, venetoclax, CD20-targeting antibodies), and pharmacological drug screening for B-cell malignancies. It is also used in comparative studies of B-cell leukemia subtypes and as a xenograft model in immunocompromised hosts. |
|---|---|
| Organism | Human |
| Tissue | Peripheral blood |
| Disease | B-cell prolymphocytic leukemia |
| Metastatic site | Peripheral blood (leukemic) |
| Applications | B-cell prolymphocytic leukemia research; mature B-cell leukemia biology; TP53-mutant drug resistance; BTK inhibitor evaluation; venetoclax sensitivity; CD20-targeting antibody testing; B-cell leukemia drug screening |
| Synonyms | JVM3 |
Characteristics
| Age | 73 years |
|---|---|
| Gender | Male |
| Ethnicity | Caucasian |
| Morphology | lymphoblastoid cells growing singly or in clumps in suspension; |
| Cell type | B lymphoblast |
| Growth properties | suspension |
Regulatory Data
| Citation | JVM-3 (Cytion catalog number 305266) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1320 |
Biomolecular Data
| Mutational profile | Mutation: p.Pro1435Leu, Heterozygous; Mutation: p.Lys601Asn, Heterozygous |
|---|
Handling
| Culture Medium | 90% RPMI 1640 + 10% h.i. FBS |
|---|---|
| Supplements | Supplement the medium with 10% heat-inactivated FBS |
| Dissociation Reagent | Not required (suspension culture) |
| Doubling time | ~30 hours |
| Subculturing | Dilute the culture to 2–5 × 10⁵ cells/ml with fresh pre-warmed complete medium every 2–3 days. Count viable cells before passaging. Centrifugation (300×g, 5 min) may be used to exchange medium when needed. |
| Split ratio | 1 to 3 |
| Seeding density | 2 to 5 × 10⁵ cells/ml |
| Fluid renewal | Every 2 to 3 days |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
Material Transfer Agreement
If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.
For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.
Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement.